Target intelligence / Profile preview

Human papillomavirus type 45 major capsid protein L1 (HPV45 L1)

Target
HPV45 L1
Molecular classification
Viral protein, Other
01

Overview

Human papillomavirus type 45 (HPV45) is a high-risk, oncogenic virus strongly associated with the development of cervical cancer and other anogenital malignancies. The major capsid protein L1 of HPV45 self-assembles into icosahedral virus-like particles (VLPs) that present highly immunogenic, surface-exposed conformational epitopes. These conformational epitopes are the primary targets for neutralizing antibodies, which block viral attachment and entry into host cells. Prophylactic vaccines, such as the 9-valent HPV vaccine (Gardasil 9) and Walrinvax, utilize recombinant HPV45 L1 VLPs to stimulate the host immune system to produce type-specific neutralizing antibodies. Targeting these conformational epitopes provides robust protection against persistent HPV45 infection and its associated precancerous lesions and cancers. However, because these epitopes are highly conformation-dependent and type-specific, maintaining structural integrity during vaccine formulation and manufacturing is a critical therapeutic challenge.

Other names
HPV45 L1 capsid proteinHuman papillomavirus type 45 L1 proteinHPV45 major capsid protein L1HPV45 L1Human papillomavirus 45 L1
02

Mechanism of action

Active immunization to induce neutralizing antibodies that block viral entry

03

Biological functions

Viral entryImmune responseOther
04

Disease associations

InfectionCancer
05

Safety considerations

Injection site reactionSyncopeSystemic adverse events (fever, headache, fatigue)Type-specific protection limits
06

Interacting drugs

Human papillomavirus 9-valent vaccine, recombinant (Gardasil 9)

1 more in the full profile.

07

Biomarkers

Anti-HPV45 L1 neutralizing antibody titerHPV45 DNA

Beyond the preview

Go deeper on Human papillomavirus type 45 major capsid protein L1 (HPV45 L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human papillomavirus type 45 major capsid protein L1 (HPV45 L1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call